Humira was efficacious and safe for treating children with moderate to severe ulcerative colitis, according to a presentation at UEG Week.“Adalimumab was generally well tolerated and no new safety signals were observed,” Nicholas M. Croft, MD, Center for Immunology, Blizard Institute, Barts and London School of Medicine, Queen Mary University of London and the Royal London Children’s Hospital, said during his presentation. “We conclude that this is an efficacious and well-tolerated treatment option for children with moderate to severe UC.”Croft and colleaguesRead More